New drug cocktail targets hard-to-treat lung cancer before surgery
NCT ID NCT07472478
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a sequence of targeted therapy (garsorasib), immunotherapy (ivonescimab), and chemotherapy before and after surgery for people with a specific type of lung cancer (KRAS G12C mutation) that can be removed. The goal is to see if this approach increases the chance of no cancer remaining at surgery and delays the cancer coming back. The study plans to enroll 32 adults with stage IB to IIIB non-small cell lung cancer who have not had prior treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Garsorasib (a KRAS G12C inhibitor) and ivonescimab (an immunotherapy) plus chemotherapy (paclitaxel and carboplatin)
- What this could lead to
- If successful, this approach could improve the chance of eliminating all cancer before surgery and delay recurrence afterward for people with this specific lung cancer mutation.
- What could go wrong
- This is a small, early-phase trial with only 32 participants, so results may not apply broadly. The drug combination also carries risks of serious side effects from chemotherapy and immunotherapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KRAS G12C LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smart drug home in on Hard-to-Treat cancers?
- Family support may be key to easing lung cancer surgery stress
- Can a drop of blood predict disease years before it strikes?
- Blood, urine, and stool may hold the key to predicting a serious side effect of lung cancer treatment
- Microwave ablation vs. radiotherapy: which Non-Surgical option works best for early lung cancer?
- Double-Targeted therapy aims to outsmart Hard-to-Treat lung cancer